Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 6.6% - Should You Sell?

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) shares traded down 6.6% on Wednesday . The company traded as low as $14.00 and last traded at $14.06. 67,075 shares changed hands during mid-day trading, a decline of 68% from the average session volume of 211,837 shares. The stock had previously closed at $15.06.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Guggenheim restated a "buy" rating and set a $19.00 price target on shares of Maze Therapeutics in a research note on Wednesday, April 2nd. Wedbush began coverage on Maze Therapeutics in a research report on Tuesday. They issued an "outperform" rating and a $17.00 target price for the company. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $23.50.

Maze Therapeutics Stock Performance

The firm's 50 day moving average is $11.46.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.39).

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in MAZE. New York State Common Retirement Fund bought a new position in shares of Maze Therapeutics in the first quarter valued at approximately $25,000. Corebridge Financial Inc. bought a new position in Maze Therapeutics in the 1st quarter valued at $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Maze Therapeutics during the 1st quarter valued at $57,000. Rhumbline Advisers bought a new position in shares of Maze Therapeutics in the first quarter worth $80,000. Finally, Deutsche Bank AG bought a new position in shares of Maze Therapeutics in the first quarter worth $98,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.